Jalasto, Juuso http://orcid.org/0000-0002-6898-972X
Luukkonen, Ritva
Lindqvist, Ari
Langhammer, Arnulf
Kankaanranta, Hannu
Backman, Helena
Rönmark, Eva
Sovijärvi, Anssi
Piirilä, Päivi
Kauppi, Paula
Funding for this research was provided by:
University of Helsinki
Article History
Received: 23 September 2023
Accepted: 16 November 2023
First Online: 19 December 2023
Declarations
:
: Dr. Kankaanranta reports fees for consultancies and lectures from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, GSK, MSD, Novartis, Orion Pharma and SanofiGenzyme. Dr. Kauppi reports consultancy fee from Sanofi and lecture fee from GSK. Dr. Kauppi also holds positions as a member of the board of the Finnish Respiratory Society and as a member of the Grant Committee of the Tuberculosis Foundation of Finland. Dr. Backman reports fees from Astra Zeneca, Boehringer-Ingelheim and GSK. Dr. Langhammer reports fees from Astra Zeneca, Boehringer-Ingelheim and Diagnostica. All other authors declare that they have nothing to disclose.
: The study was approved by the ethics committee of the Department of Medicine, Helsinki University Central Hospital. The subjects filled in a written informed consent form.
: All participants of the study have signed an informed consent for research and publication.